Cingulate (CINGW) Projected to Post Quarterly Earnings on Friday
by Jessica Moore · The Cerbat GemCingulate (NASDAQ:CINGW – Get Free Report) will likely be releasing its results before the market opens on Friday, March 6th. Analysts expect Cingulate to post earnings of ($0.6320) per share for the quarter.
Cingulate Trading Up 12.3%
Cingulate stock opened at $0.04 on Wednesday. The stock has a 50-day moving average price of $0.07 and a two-hundred day moving average price of $0.06. Cingulate has a 12 month low of $0.02 and a 12 month high of $0.18.
Cingulate Company Profile
Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.